IP Library Granted Patent US 7,959,659
Granted Patent B2
US 7,959,659 · App. 11/027,822 · Granted Jun 14, 2011

High-density lipoprotein coated medical devices

Assignee: Advanced Cardiovascular Systems, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,959,659
App. No.
11/027,822
Granted
Jun 14, 2011
Kind
B2
Abstract

An implantable medical device is disclosed comprising a high-density lipoprotein (HDL), recombinant HDL, high-density lipoprotein mimics (HDLm), or a combination thereof. Method are also disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.

Claims (17)

1. An implantable medical device, comprising

a coating comprising a hydrophobic polymer and a high-density lipoprotein mimic (HDLm) and a biobeneficial material,

wherein the hydrophobic polymer is a polyester selected from the group consisting of poly(D, L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D, L-lactic acid-co-glycolic acid) (PDLLGA), poly(glycolic acid) (PGA), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), polycaprolactone (PCL), and a combination thereof,

wherein the biobeneficial material is a block copolymer having flexible poly(ethylene glycol) and poly(butylene terephthalate) blocks,

wherein the implantable medical device comprises a stent suitable for use in a blood vessel, and

wherein HDLm comprises a polypeptide moiety that mimics the structure or function of a domain of apoA-I, apoA-II, or AI/AII-HDL.

2. The implantable medical device of claim 1 , wherein the coating comprises a polypeptide moiety that mimics the structure or function of a domain of AI/AII-HDL.

3. The implantable medical device of claim 2 , wherein the stent is a bioabsorbable polymeric stent and the high-density lipoprotein (HDL), recombinant HDL, high-density lipoprotein mimic (HDLm), or a combination thereof is incorporated in the body of the stent.

4. The implantable medical device of claim 1 , wherein the stent further comprises a high-density lipoprotein (HDL), recombinant HDL, or a combination thereof incorporated in the coating.

5. The implantable medical device of claim 4 , wherein the coating includes a reservoir region having the high-density lipoprotein mimic (HDLm) and the high-density lipoprotein (HDL), recombinant HDL, or a combination thereof and a topcoat region over the reservoir region.

6. The implantable medical device of claim 5 , wherein the coating additionally includes a primer region beneath the reservoir region.

7. The implantable medical device of claim 4 , wherein the coating includes a reservoir region having the high-density lipoprotein mimic (HDLm) and the high-density lipoprotein (HDL), recombinant HDL, or a combination thereof and a primer region beneath the reservoir region.

8. The implantable medical device of claim 7 , wherein the coating additionally includes a topcoat region over the reservoir region.

9. The implantable medical device of claim 1 , additionally including a drug.

10. The implantable medical device of claim 9 , wherein the drug is everolimus, zotarolimus, paclitaxel, docetaxel, paclitaxel derivatives, or rapamycin.

11. A method of treating a medical condition, comprising implanting in a human being a medical device as defined in claim 1 , wherein the medical condition is selected from the group consisting of vulnerable plaque, restenosis, stenosis, atherosclerosis, thrombosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, and a combination thereof.

12. A method of treating a medical condition, comprising implanting in a human being a medical device as defined in claim 9 , wherein the medical condition is selected from the group consisting of vulnerable plaque, restenosis, stenosis, atherosclerosis, thrombosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, and a combination thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 29, 2018
From: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
To: ABBOTT CARDIOVASCULAR SYSTEMS INC.
Reel/Frame 045777/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2005
From: DING, NI
To: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
Reel/Frame 016134/0727 →
Continuity (3)
Continuation In Part 11001225 · Nov 30, 2004
Provisional Application 60534045 · Jan 2, 2004
Related Publication 20050175666A1 · Aug 11, 2005